Patient Safety Organizations: Voluntary Relinquishment for the Zephcare PSO, 80537-80538 [2022-28432]
Download as PDF
Federal Register / Vol. 87, No. 250 / Friday, December 30, 2022 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
that a proposed transmission facility is
in the public convenience and necessity
when considering whether the costs of
that transmission facility may be
recovered through a formula rate?
Should the Commission prohibit the
recovery of transmission project costs
through a formula rate if those projects
have not been subject to a robust state
CPCN process? Why or why not? Should
the Commission accept as self-proving
an attestation from state regulators that
such a robust CPCN process is used in
their state? If yes, are there specific
factors or features of a state regulator’s
CPCN process that indicate whether a
potential transmission facility has been
robustly evaluated for need and cost? If
not, are there other indicators (e.g.,
other regulatory determinations, thirdparty analyses, legislative reports, etc.)
that demonstrate that the need for and
costs of a potential transmission facility
have been robustly reviewed? What are
the advantages and disadvantages of this
approach?
c. If formula rate treatment is not
permitted, how should costs related to
the new transmission project or
transmission facility be separated out
for recovery in a stated rate proceeding
(e.g., should all costs related to the
transmission facility be excluded from
formula rate recovery, or only capital
costs)? How could the timing of the state
regulatory proceeding impact a public
utility transmission provider’s ability to
file for cost recovery of proposed
transmission facilities subject to CPCN
review? How, if at all, would the
inability to recover the costs of certain
transmission facilities through a public
utility transmission provider’s formula
rate impact its annual formula rate
proceedings?
d. If the Commission determines that
a potential transmission facility has not
been robustly evaluated at the state level
for need and cost, are there other
regulatory requirements that the
Commission could impose short of
requiring a transmission facility’s costs
to be recovered through stated rates
rather than formula rates? If so, what
options are available and what are the
pros and cons of those options?
Other Questions
12. Some panelists argued that the
timing of cost management or oversight
mechanisms is relevant to ensuring cost
effectiveness, contending that cost
scrutiny must be applied to decisions
during the local or regional transmission
planning phase in order to influence
those decisions. Do you agree, and if so
why or why not? What are the
possibilities for facilitating timely cost
management before money is spent on
VerDate Sep<11>2014
17:08 Dec 29, 2022
Jkt 259001
transmission projects (aside from
planning costs)?
[FR Doc. 2022–28454 Filed 12–29–22; 8:45 am]
BILLING CODE 6717–01–P
ENVIRONMENTAL PROTECTION
AGENCY
80537
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Patient Safety Organizations:
Voluntary Relinquishment for the
Zephcare PSO
Agency for Healthcare Research
and Quality (AHRQ), Department of
Health and Human Services (HHS).
ACTION: Notice of delisting.
AGENCY:
[FRL OP–OFA–050]
Environmental Impact Statements;
Notice of Availability
Responsible Agency: Office of Federal
Activities, General Information 202–
564–5632 or https://www.epa.gov/nepa.
Weekly receipt of Environmental Impact
Statements (EIS) Filed December 19,
2022 10 a.m. EST Through December
23, 2022 10 a.m. EST Pursuant to 40
CFR 1506.9.
Notice
Section 309(a) of the Clean Air Act
requires that EPA make public its
comments on EISs issued by other
Federal agencies. EPA’s comment letters
on EISs are available at: https://
cdxapps.epa.gov/cdx-enepa-II/public/
action/eis/search.
EIS No. 20220193, Final, FEMA, NJ,
ADOPTION—Rebuild by Design—
Hudson River (RBD–HR), Review
Period Ends: 01/30/2023, Contact:
John McKee 202–704–7160.
The Federal Emergency Management
Agency (FEMA) has adopted the
Department of Housing and Urban
Development’s Final EIS No. 20170101,
filed 6/8/2017 with the Environmental
Protection Agency. The FEMA was not
a cooperating agency on this project.
Therefore, republication of the
document is necessary under Section
1506.3(c) of the CEQ regulations.
Amended Notice
EIS No. 20220175, Draft, BIA, DOI, OR,
Coquille Indian Tribe Fee to Trust
Gaming Facility Project, Comment
Period Ends: 02/23/2023, Contact:
Tobiah Mogavero 435–210–0509.
Revision to FR Notice Published 11/
25/2022; Extending the Comment Period
from 01/09/2023 to 02/23/2023.
Dated: December 23, 2022.
Cindy S. Barger,
Director, NEPA Compliance Division, Office
of Federal Activities.
[FR Doc. 2022–28438 Filed 12–29–22; 8:45 am]
BILLING CODE 6560–50–P
PO 00000
Frm 00016
Fmt 4703
Sfmt 4703
The Patient Safety and
Quality Improvement Final Rule
(Patient Safety Rule) authorizes AHRQ,
on behalf of the Secretary of HHS, to list
as a patient safety organization (PSO) an
entity that attests that it meets the
statutory and regulatory requirements
for listing. A PSO can be ‘‘delisted’’ by
the Secretary if it is found to no longer
meet the requirements of the Patient
Safety and Quality Improvement Act of
2005 (Patient Safety Act) and Patient
Safety Rule, when a PSO chooses to
voluntarily relinquish its status as a
PSO for any reason, or when a PSO’s
listing expires. AHRQ accepted a
notification of proposed voluntary
relinquishment from the Zephcare PSO,
PSO number P0200, of its status as a
PSO, and has delisted the PSO
accordingly.
SUMMARY:
The delisting was effective at
12:00 Midnight ET (2400) on December
8, 2022.
ADDRESSES: The directories for both
listed and delisted PSOs are ongoing
and reviewed weekly by AHRQ. Both
directories can be accessed
electronically at the following HHS
website: https://www.pso.ahrq.gov/
listed.
DATES:
FOR FURTHER INFORMATION CONTACT:
Cathryn Bach, Center for Quality
Improvement and Patient Safety, AHRQ,
5600 Fishers Lane, MS 06N100B,
Rockville, MD 20857; Telephone (toll
free): (866) 403–3697; Telephone (local):
(301) 427–1111; TTY (toll free): (866)
438–7231; TTY (local): (301) 427–1130;
Email: pso@ahrq.hhs.gov.
SUPPLEMENTARY INFORMATION:
Background
The Patient Safety Act, 42 U.S.C.
299b–21 to 299b–26, and the related
Patient Safety Rule, 42 CFR part 3,
published in the Federal Register on
November 21, 2008 (73 FR 70732–
70814), establish a framework by which
individuals and entities that meet the
definition of provider in the Patient
Safety Rule may voluntarily report
information to PSOs listed by AHRQ, on
E:\FR\FM\30DEN1.SGM
30DEN1
80538
Federal Register / Vol. 87, No. 250 / Friday, December 30, 2022 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
a privileged and confidential basis, for
the aggregation and analysis of patient
safety work product.
The Patient Safety Act authorizes the
listing of PSOs, which are entities or
component organizations whose
mission and primary activity are to
conduct activities to improve patient
safety and the quality of health care
delivery.
HHS issued the Patient Safety Rule to
implement the Patient Safety Act.
AHRQ administers the provisions of the
Patient Safety Act and Patient Safety
Rule relating to the listing and operation
of PSOs. The Patient Safety Rule
authorizes AHRQ to list as a PSO an
entity that attests that it meets the
statutory and regulatory requirements
for listing. A PSO can be ‘‘delisted’’ if
it is found to no longer meet the
requirements of the Patient Safety Act
and Patient Safety Rule, when a PSO
chooses to voluntarily relinquish its
status as a PSO for any reason, or when
a PSO’s listing expires. Section 3.108(d)
of the Patient Safety Rule requires
AHRQ to provide public notice when it
removes an organization from the list of
PSOs.
AHRQ has accepted a notification of
proposed voluntary relinquishment
from the Zephcare PSO to voluntarily
relinquish its status as a PSO.
Accordingly, the Zephcare PSO, PSO
number P0200, was delisted effective at
12:00 Midnight ET (2400) on December
8, 2022.
Zephcare PSO has patient safety work
product (PSWP) in its possession. The
PSO will meet the requirements of
section 3.108(c)(2)(i) of the Patient
Safety Rule regarding notification to
providers that have reported to the PSO
and of section 3.108(c)(2)(ii) regarding
disposition of PSWP consistent with
section 3.108(b)(3). According to section
3.108(b)(3) of the Patient Safety Rule,
the PSO has 90 days from the effective
date of delisting and revocation to
complete the disposition of PSWP that
is currently in the PSO’s possession.
More information on PSOs can be
obtained through AHRQ’s PSO website
at https://www.pso.ahrq.gov.
Dated: December 23, 2022.
Marquita Cullom,
Associate Director.
[FR Doc. 2022–28432 Filed 12–29–22; 8:45 am]
BILLING CODE 4160–90–P
VerDate Sep<11>2014
17:08 Dec 29, 2022
Jkt 259001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Solicitation for Nominations for
Members of the U.S. Preventive
Services Task Force (USPSTF)
Agency for Healthcare Research
and Quality (AHRQ), HHS.
ACTION: Solicits nominations for new
members of the USPSTF.
AGENCY:
The Agency for Healthcare
Research and Quality (AHRQ) invites
nominations of individuals qualified to
serve as members of the U.S. Preventive
Services Task Force (USPSTF).
DATES: Nominations must be received
electronically by March 15th of a given
year to be considered for appointment to
begin in January of the following year.
ADDRESSES: Submit your responses
electronically via: https://uspstf
nominations.ahrq.gov/register.
FOR FURTHER INFORMATION CONTACT:
Lydia Hill at (301) 427–1587.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Arrangement for Public Inspection
Nominations and applications are
kept on file at the Center for Evidence
and Practice Improvement, AHRQ, and
are available for review during business
hours. AHRQ does not reply to
individual nominations, but considers
all nominations in selecting members.
Information regarded as private and
personal, such as a nominee’s social
security number, home and email
addresses, home telephone and fax
numbers, or names of family members
will not be disclosed to the public in
accord with the Freedom of Information
Act. 5 U.S.C. 552(b)(6); 45 CFR 5.31(f).
Nomination Submissions
Nominations must be submitted
electronically, and should include:
1. The applicant’s current curriculum
vitae and contact information, including
mailing address, and email address; and
2. A letter explaining how this
individual meets the qualification
requirements and how he or she would
contribute to the USPSTF. The letter
should also attest to the nominee’s
willingness to serve as a member of the
USPSTF.
AHRQ will later ask people under
serious consideration for USPSTF
membership to provide detailed
information that will permit evaluation
of possible significant conflicts of
interest. Such information will concern
matters such as financial holdings,
consultancies, non-financial scientific
PO 00000
Frm 00017
Fmt 4703
Sfmt 4703
interests, and research grants or
contracts.
To obtain a diversity of perspectives,
AHRQ particularly encourages
nominations of women, members of
underrepresented populations, and
persons with disabilities. Interested
individuals can nominate themselves.
Organizations and individuals may
nominate one or more people qualified
for membership on the USPSTF at any
time. Individuals nominated prior to
March 15, 2022, who continue to have
interest in serving on the USPSTF
should be re-nominated.
Qualification Requirements
To qualify for the USPSTF and
support its mission, an applicant or
nominee should, at a minimum,
demonstrate knowledge, expertise, and
national leadership in the following
areas:
1. The critical evaluation of research
published in peer-reviewed literature
and in the methods of evidence review;
2. Clinical prevention, health
promotion and primary health care; and
3. Implementation of evidence-based
recommendations in clinical practice
including at the clinician-patient level,
practice level, and health-system level.
Additionally, the Task Force benefits
from members with expertise in the
following areas:
D Public Health
D Health Equity and The Reduction of
Health Disparities
D Application of Science to Health
Policy
D Decision modeling
D Dissemination and Implementation
D Behavioral Medicine/Clinical Health
Psychology
D Communication of Scientific Findings
to Multiple Audiences Including
Health Care Professionals, Policy
Makers, and the General Public.
Candidates with experience and skills
in any of these areas should highlight
them in their nomination materials.
Applicants must have no substantial
conflicts of interest, whether financial,
professional, or intellectual, that would
impair the scientific integrity of the
work of the USPSTF and must be
willing to complete regular conflict of
interest disclosures.
Applicants must have the ability to
work collaboratively with a team of
diverse professionals who support the
mission of the USPSTF. Applicants
must have adequate time to contribute
substantively to the work products of
the USPSTF.
Nominee Selection
Nominated individuals will be
selected for the USPSTF on the basis of
E:\FR\FM\30DEN1.SGM
30DEN1
Agencies
[Federal Register Volume 87, Number 250 (Friday, December 30, 2022)]
[Notices]
[Pages 80537-80538]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-28432]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Patient Safety Organizations: Voluntary Relinquishment for the
Zephcare PSO
AGENCY: Agency for Healthcare Research and Quality (AHRQ), Department
of Health and Human Services (HHS).
ACTION: Notice of delisting.
-----------------------------------------------------------------------
SUMMARY: The Patient Safety and Quality Improvement Final Rule (Patient
Safety Rule) authorizes AHRQ, on behalf of the Secretary of HHS, to
list as a patient safety organization (PSO) an entity that attests that
it meets the statutory and regulatory requirements for listing. A PSO
can be ``delisted'' by the Secretary if it is found to no longer meet
the requirements of the Patient Safety and Quality Improvement Act of
2005 (Patient Safety Act) and Patient Safety Rule, when a PSO chooses
to voluntarily relinquish its status as a PSO for any reason, or when a
PSO's listing expires. AHRQ accepted a notification of proposed
voluntary relinquishment from the Zephcare PSO, PSO number P0200, of
its status as a PSO, and has delisted the PSO accordingly.
DATES: The delisting was effective at 12:00 Midnight ET (2400) on
December 8, 2022.
ADDRESSES: The directories for both listed and delisted PSOs are
ongoing and reviewed weekly by AHRQ. Both directories can be accessed
electronically at the following HHS website: https://www.pso.ahrq.gov/listed.
FOR FURTHER INFORMATION CONTACT: Cathryn Bach, Center for Quality
Improvement and Patient Safety, AHRQ, 5600 Fishers Lane, MS 06N100B,
Rockville, MD 20857; Telephone (toll free): (866) 403-3697; Telephone
(local): (301) 427-1111; TTY (toll free): (866) 438-7231; TTY (local):
(301) 427-1130; Email: [email protected].
SUPPLEMENTARY INFORMATION:
Background
The Patient Safety Act, 42 U.S.C. 299b-21 to 299b-26, and the
related Patient Safety Rule, 42 CFR part 3, published in the Federal
Register on November 21, 2008 (73 FR 70732-70814), establish a
framework by which individuals and entities that meet the definition of
provider in the Patient Safety Rule may voluntarily report information
to PSOs listed by AHRQ, on
[[Page 80538]]
a privileged and confidential basis, for the aggregation and analysis
of patient safety work product.
The Patient Safety Act authorizes the listing of PSOs, which are
entities or component organizations whose mission and primary activity
are to conduct activities to improve patient safety and the quality of
health care delivery.
HHS issued the Patient Safety Rule to implement the Patient Safety
Act. AHRQ administers the provisions of the Patient Safety Act and
Patient Safety Rule relating to the listing and operation of PSOs. The
Patient Safety Rule authorizes AHRQ to list as a PSO an entity that
attests that it meets the statutory and regulatory requirements for
listing. A PSO can be ``delisted'' if it is found to no longer meet the
requirements of the Patient Safety Act and Patient Safety Rule, when a
PSO chooses to voluntarily relinquish its status as a PSO for any
reason, or when a PSO's listing expires. Section 3.108(d) of the
Patient Safety Rule requires AHRQ to provide public notice when it
removes an organization from the list of PSOs.
AHRQ has accepted a notification of proposed voluntary
relinquishment from the Zephcare PSO to voluntarily relinquish its
status as a PSO. Accordingly, the Zephcare PSO, PSO number P0200, was
delisted effective at 12:00 Midnight ET (2400) on December 8, 2022.
Zephcare PSO has patient safety work product (PSWP) in its
possession. The PSO will meet the requirements of section
3.108(c)(2)(i) of the Patient Safety Rule regarding notification to
providers that have reported to the PSO and of section 3.108(c)(2)(ii)
regarding disposition of PSWP consistent with section 3.108(b)(3).
According to section 3.108(b)(3) of the Patient Safety Rule, the PSO
has 90 days from the effective date of delisting and revocation to
complete the disposition of PSWP that is currently in the PSO's
possession.
More information on PSOs can be obtained through AHRQ's PSO website
at https://www.pso.ahrq.gov.
Dated: December 23, 2022.
Marquita Cullom,
Associate Director.
[FR Doc. 2022-28432 Filed 12-29-22; 8:45 am]
BILLING CODE 4160-90-P